SEC and FDA Sign Memorandum of Understanding to Enhance Cooperation

On August 31, 2026, the U.S. Securities and Exchange Commission (SEC) and the Food and Drug Administration (FDA) announced they have entered into a Memorandum of Understanding (MOU) to enhance cooperation in their regulatory and enforcement responsibilities. The MOU establishes a framework for information sharing between the agencies, relevant to both missions of ensuring financial market integrity and protecting public health. SEC Chairman Paul S. Atkins and Acting FDA Commissioner Kyle Diamantras emphasized the importance of the partnership in improving transparency and compliance, particularly regarding FDA-related disclosures by public companies. The MOU is effective for three years and may be extended or modified by mutual consent.